<![CDATA[Graves Disease]]> https://www.leadingmarketresearch.com/pharmaceuticals-biotechnology/pharmaceuticals/diseases-conditions/graves-disease Sun, 12 Apr 2026 17:15:19 +0000 Zend_Feed http://blogs.law.harvard.edu/tech/rss <![CDATA[Graves Diseases - Pipeline Review, H2 2017]]> https://www.leadingmarketresearch.com/graves-diseases-pipeline-review-h2-2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graves Diseases - Pipeline Review, H2 2017, provides an overview of the Graves Diseases (Hormonal Disorders) pipeline landscape.

Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism). Symptoms include anxiety, weight loss, change in menstrual cycles, erectile dysfunction, bulging eyes and irregular heartbeat. Risk factors include family history, age, autoimmune disorders, smoking and pregnancy. Treatment includes anti-thyroid medications, beta blockers and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graves Diseases - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Graves Diseases (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descripti...

$2,000.00
]]> Thu, 18 Jan 2018 15:45:29 +0000 <![CDATA[Graves Disease  - Market Insights, Epidemiology and Market Forecast-2023]]> https://www.leadingmarketresearch.com/graves-disease-market-insights-epidemiology-and-market-forecast-4920 Note*: This report requires 7-10 business days to complete. DelveInsight’s Graves Disease - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Crohn’s disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Graves Disease forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Graves Disease till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Graves Disease market. • Identifying patient populations in the global “Graves Diseasemarket to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Graves Disease therapeutics in each of the markets covered. • To understand th...
$4,950.00
]]> Tue, 25 Apr 2017 20:08:12 +0000 <![CDATA[Graft Versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023]]> https://www.leadingmarketresearch.com/graft-versus-host-disease-gvhd-market-insights-epidemiology-and-market-196626 DelveInsight’s “Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023” report provides an overview of the disease and global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic stem cell transplantations (HSCTs) and Graft Versus Host Disease (GVHD) based upon the sub-types of GVHD along with the type of donor involved in the HSCTs, for the forecast period (2013-2023). The report also includes global market size of the Graft Versus Host Disease (GVHD) for the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan. GVHD is one of the severe complications associated with Hematopoietic stem cell transplantations (HSCTs). DelveInsight forecasts predict an on-going increase in HSCTs in the near future which shall lead to subsequent increase in the patient population of GVHD. According to DelveInsight’s estimates, the total number of diagnosed incident cases of Hematopoietic Stem Cell Transplants (HSCTs) shall increase at a Compound Annual Growth Rate (CAGR) of 2.92%, 2.73% and 2.71% ...
$4,950.00
]]> Thu, 20 Apr 2017 12:12:19 +0000 <![CDATA[Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023- EU5]]> https://www.leadingmarketresearch.com/graft-versus-host-disease-gvhd-market-insights-epidemiology-and-market-378 DelveInsight’s “Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023-EU5” report provides an overview of the disease and global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic stem cell transplantations (HSCTs) and Graft Versus Host Disease (GVHD) based upon the sub-types of GVHD along with the type of donor involved in the HSCTs, for the forecast period (2013-2023). GVHD is one of the severe complications associated with Hematopoietic stem cell transplantations (HSCTs). DelveInsight forecasts predict an on-going increase in HSCTs in the near future which shall lead to subsequent increase in the patient population of GVHD. According to DelveInsight’s estimates, the total number of diagnosed incident cases of Hematopoietic Stem Cell Transplants (HSCTs) shall increase at a Compound Annual Growth Rate (CAGR) of 2.71% from 2013-2023 and reach up to 30,328 cases in the year 2023. The incident rate of GVHD in unrelated donor (URD) is much higher in comparison to the sibling donors (SD), irrespect...
$2,450.00
]]> Thu, 20 Apr 2017 12:12:19 +0000 <![CDATA[Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023- Japan]]> https://www.leadingmarketresearch.com/graft-versus-host-disease-gvhd-market-insights-epidemiology-and-market-60 DelveInsight’s “Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023-Japan” report provides an overview of the disease and global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic stem cell transplantations (HSCTs) and Graft Versus Host Disease (GVHD) based upon the sub-types of GVHD along with the type of donor involved in the HSCTs, for the forecast period (2013-2023). The report also includes global market size of the Graft Versus Host Disease (GVHD) for Japan. GVHD is one of the severe complications associated with Hematopoietic stem cell transplantations (HSCTs). DelveInsight forecasts predict an on-going increase in HSCTs in the near future which shall lead to subsequent increase in the patient population of GVHD. According to DelveInsight’s estimates, the total number of diagnosed incident cases of Hematopoietic Stem Cell Transplants (HSCTs) shall increase at a Compound Annual Growth Rate (CAGR) of 2.73% from 2013-2023 and reach up to 7,025 cases in the year 2023. The incident rate of...
$1,750.00
]]> Thu, 20 Apr 2017 12:12:19 +0000 <![CDATA[Graft Versus Host Disease (GVHD) - Epidemiology Insights-2023]]> https://www.leadingmarketresearch.com/graft-versus-host-disease-gvhd-epidemiology-insights-2023 DelveInsight’s “Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023-Global” report provides an overview of the disease and global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic stem cell transplantations (HSCTs) and Graft Versus Host Disease (GVHD) based upon the sub-types of GVHD along with the type of donor involved in the HSCTs, for the forecast period (2013-2023) in the 7MM. GVHD is one of the severe complications associated with Hematopoietic stem cell transplantations (HSCTs). DelveInsight forecasts predict an on-going increase in HSCTs in the near future which shall lead to subsequent increase in the patient population of GVHD. According to DelveInsight’s estimates, the total number of diagnosed incident cases of Hematopoietic Stem Cell Transplants (HSCTs) shall increase at a Compound Annual Growth Rate (CAGR) of 2.80% from 2013-2023. The incident rate of GVHD in unrelated donor (URD) is much higher in comparison to the sibling donors (SD), irrespective of the sub-types i.e., acute ...
$2,750.00
]]> Thu, 20 Apr 2017 12:12:19 +0000 <![CDATA[Graft Versus Host Disease (GVHD) - Epidemiology Insights-2023- United States]]> https://www.leadingmarketresearch.com/graft-versus-host-disease-gvhd-epidemiology-insights-2023-united-state DelveInsight’s “Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023-United States” report provides an overview of the disease and global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic stem cell transplantations (HSCTs) and Graft Versus Host Disease (GVHD) based upon the sub-types of GVHD along with the type of donor involved in the HSCTs, for the forecast period (2013-2023). GVHD is one of the severe complications associated with Hematopoietic stem cell transplantations (HSCTs). DelveInsight forecasts predict an on-going increase in HSCTs in the near future which shall lead to subsequent increase in the patient population of GVHD. According to DelveInsight’s estimates, the total number of diagnosed incident cases of Hematopoietic Stem Cell Transplants (HSCTs) shall increase at a Compound Annual Growth Rate (CAGR) of 2.92% from 2013-2023 and reach up to 27,114 cases in the year 2023. The incident rate of GVHD in unrelated donor (URD) is much higher in comparison to the sibling donors (SD),...
$1,750.00
]]> Thu, 20 Apr 2017 12:12:19 +0000 <![CDATA[Graft Versus Host Disease (GVHD) - Epidemiology Insights-2023- Japan]]> https://www.leadingmarketresearch.com/graft-versus-host-disease-gvhd-epidemiology-insights-2023-japan DelveInsight’s “Graft versus Host Disease (GVHD) - - Epidemiology Insights-2023-Japan” report provides an overview of the disease and global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic stem cell transplantations (HSCTs) and Graft Versus Host Disease (GVHD) based upon the sub-types of GVHD along with the type of donor involved in the HSCTs, for the forecast period (2013-2023). GVHD is one of the severe complications associated with Hematopoietic stem cell transplantations (HSCTs). DelveInsight forecasts predict an on-going increase in HSCTs in the near future which shall lead to subsequent increase in the patient population of GVHD. According to DelveInsight’s estimates, the total number of diagnosed incident cases of Hematopoietic Stem Cell Transplants (HSCTs) shall increase at a Compound Annual Growth Rate (CAGR) of 2.73% from 2013-2023 and reach up to 7,025 cases in the year 2023. The incident rate of GVHD in unrelated donor (URD) is much higher in comparison to the sibling donors (SD), irrespective of the sub-types i.e....
$1,450.00
]]> Thu, 20 Apr 2017 12:12:19 +0000 <![CDATA[Graft Versus Host Disease (GVHD) - Epidemiology Insights-2023- EU5]]> https://www.leadingmarketresearch.com/graft-versus-host-disease-gvhd-epidemiology-insights-2023-eu5 DelveInsight’s “Graft versus Host Disease (GVHD) - Epidemiology Insights, 2023-EU5” report provides an overview of the disease and global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic stem cell transplantations (HSCTs) and Graft Versus Host Disease (GVHD) based upon the sub-types of GVHD along with the type of donor involved in the HSCTs, for the forecast period (2013-2023). GVHD is one of the severe complications associated with Hematopoietic stem cell transplantations (HSCTs). DelveInsight forecasts predict an on-going increase in HSCTs in the near future which shall lead to subsequent increase in the patient population of GVHD. According to DelveInsight’s estimates, the total number of diagnosed incident cases of Hematopoietic Stem Cell Transplants (HSCTs) shall increase at a Compound Annual Growth Rate (CAGR) of 2.71% from 2013-2023 and reach up to 30,328 cases in the year 2023. The incident rate of GVHD in unrelated donor (URD) is much higher in comparison to the sibling donors (SD), irrespective of the sub-types i.e., ...
$1,750.00
]]> Thu, 20 Apr 2017 12:12:19 +0000 <![CDATA[Graves Diseases - Pipeline Review, H2 2016]]> https://www.leadingmarketresearch.com/graves-diseases-pipeline-review-h2-2016

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Graves Diseases Overview 6
Therapeutics Development 7
Pipeline Products for Graves Diseases - Overview 7
Graves Diseases - Therapeutics under Development by Companies 8
Graves Diseases - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Graves Diseases - Products under Development by Companies 11
Graves Diseases - Companies Involved in Therapeutics Development 12
Apitope International NV 12
Nova Therapeutics LLC 13
Novartis AG 14
Omeros Corp 15
Rodos BioTarget GmbH 16
Graves Diseases - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
ATXGD-59 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
CFZ-533 - Drug Profile 27
Product Descriptio...

$2,000.00
]]> Fri, 07 Apr 2017 13:51:23 +0000 <![CDATA[Graves Disease  - Market Insights, Epidemiology and Market Forecast-2023]]> https://www.leadingmarketresearch.com/graves-disease-market-insights-epidemiology-and-market-forecast-2023 DelveInsight’s Graves Disease - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Graves Disease for the seven major markets i.e. United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Graves Disease forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Graves Disease till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Graves Disease market. • Identifying patient populations in the global “Graves Disease market to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Graves Disease therapeutics in each of the markets covered. • To understand the future market competition in the global Graves Disease thera...
$4,950.00
]]> Wed, 24 Aug 2016 13:19:26 +0000